Freeze-Thaw Cycle

Freeze-Thaw Cycle refers to repeated freezing and thawing events experienced by biologic materials during storage, transport, or manufacturing operations, potentially impacting stability and product quality. These cycles can induce protein aggregation, precipitation, denaturation, and changes in particle profiles, particularly for sensitive monoclonal antibodies and enzymes. Freeze-thaw stress also affects viral vectors and cellular products through loss of potency or viability.

The biopharmaceutical industry controls freeze-thaw exposure through validated storage conditions, defined handling procedures, and stability studies establishing allowable cycle limits. Cryoprotectants and stabilising excipients reduce damage during freezing, while controlled-rate freezing improves reproducibility. Analytical testing monitors aggregation, potency, and particulates before and after freeze-thaw challenges. Regulatory submissions include data supporting storage claims and handling instructions. As supply chains globalise and cold chain distribution expands, freeze-thaw control remains critical for ensuring consistent product performance.